|
GB0329732D0
|
|
Methods for the treatment of testosterone deficiency and conditions characterised by terstosterone deficiency
|
|
GB0329731D0
|
|
Methods for the treatment of gonadal sex hormone deficiency and conditions characterised by gonadal sex hormone deficiency
|
|
GB0230348D0
|
|
Methods for the treatment of gonadal sex hormone deficiency and conditions characterised by gonadal sex hormone deficiency
|
|
GB0230346D0
|
|
Methods for the treatment of testosterone deficiency and conditions characterised by testosterone deficiency
|
|
GB0229748D0
|
|
Methods for the treatment of testosterone deficiency and conditions characterised by testosterone deficiency
|
|
US7217505B2
|
|
Method for determining whether condition is symptom of metabolic syndrome
|
|
GB0118299D0
|
|
Pharmaceutical formulations
|
|
GB0118300D0
|
|
Formulations
|
|
US2002055512A1
|
|
Compositions for delivery of a cortisol antagonist
|
|
US6642236B1
|
|
Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
|
|
CN1433302A
|
|
Use of cortisol antagonists in the treatment for heat failure
|
|
GB0001449D0
|
|
Compositions
|
|
GB9915625D0
|
|
Method
|
|
AU6302398A
|
|
Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
|
|
CZ298999A3
|
|
Process for preparing a medicament, compound therapeutical preparation, a mixture and a kit containing cortisol synthesis inhibitor and growth hormone
|
|
AU5917396A
|
|
Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome
|
|
NZ273710A
|
|
use of ketoconazole or a derivative which is a cortisol synthesis inhibitor in medicaments for treatment of type II diabetes
|
|
US5849740A
|
|
Methods for using ketoconazole and related substances in medicaments for treatment of type II diabetes
|
